Effects of Low-dose Methotrexate With Methimazole in Patients With Graves’ Disease: Results of a Randomized Clinical Trial

甲氨蝶呤 格雷夫斯病 中止 医学 随机对照试验 甲状腺机能正常 背景(考古学) 疾病 特拉布 内科学 胃肠病学 甲状腺 古生物学 生物
作者
Pu Xie,Liyun Shen,Rongguang Peng,Yanqiu Wang,Qinglei Yin,Xinxin Chen,Jin Zhou,Guang Ning,Weiqing Wang,Shu Wang,Yulin Zhou
出处
期刊:The Journal of Clinical Endocrinology and Metabolism [Oxford University Press]
卷期号:110 (2): 489-497 被引量:13
标识
DOI:10.1210/clinem/dgae472
摘要

CONTEXT: Supplemental methotrexate (MTX) may affect the clinical course of Graves' disease (GD). OBJECTIVE: To evaluate the efficacy of add-on MTX on medical treatment in GD. DESIGN: Prospective, open-label, randomized supplementation controlled trial. SETTING: Academic endocrine outpatient clinic. PATIENTS: One hundred fifty-three untreated hyperthyroid patients with GD. INTERVENTION: Patients received MTX 10 mg/w with methimazole (MMI) or MMI only. MTX and MMI were discontinued at months 12 to 18 in euthyroid patients. MAIN OUTCOME MEASURES: Discontinuation rate at month 18 in each group. RESULTS: In the MTX with MMI group, the discontinuation rate was higher than the MMI group at months 15 to 18 [50.0 vs 33.3%, P = .043, 95% confidence interval (CI) 1.020-3.922; and 55.6 vs 38.9%, P = .045, 95% CI 1.011-3.815, respectively). The decrease in thyrotropin-related antibodies (TRAb) levels in the MTX with MMI group was significant from baseline to month 6 compared to the MMI alone group [MTX + MMI 67.22% (43.12-80.32), MMI 54.85% (33.18-73.76), P = .039] and became more significant from month 9 [MTX + MMI 77.79% (62.27-88.18), MMI 69.55% (50.50-83.22), P = .035] to month 18 (P < .01 in 15-18 months). A statistically significant difference was seen between the levels of TRAb in the MTX with MMI group and the MMI group at 9 to 18 months. There were no significant differences in the levels of free T3, free T4, and TSH between the 2 groups. No serious drug-related adverse events were observed in either group (P = .771). CONCLUSION: Supplemental MTX with MMI resulted in a higher discontinuation rate and improvement in decreased TRAb levels to homeostatic levels faster than methimazole treatment alone at months 12 to 18.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zyj发布了新的文献求助10
刚刚
刚刚
被迫做科研的老登完成签到,获得积分10
刚刚
daomaihu发布了新的文献求助100
1秒前
张维完成签到,获得积分10
1秒前
pjx完成签到,获得积分10
2秒前
学必困完成签到 ,获得积分10
2秒前
3秒前
搜集达人的应助被初景采纳,获得10
4秒前
九天春雪发布了新的文献求助10
5秒前
coco完成签到 ,获得积分10
5秒前
刘刘宇航发布了新的文献求助10
6秒前
6秒前
风移完成签到,获得积分10
6秒前
Jasper的应助被11采纳,获得10
8秒前
初景发布了新的文献求助10
8秒前
9秒前
桐桐的应助被xiaoxuey采纳,获得10
9秒前
隐形曼青的应助被敏感墨镜采纳,获得10
11秒前
11秒前
12秒前
12秒前
cmwxh发布了新的文献求助10
14秒前
16秒前
bw完成签到,获得积分10
17秒前
为467u发布了新的文献求助10
17秒前
18秒前
滴滴答答发布了新的文献求助10
18秒前
hx完成签到,获得积分10
18秒前
u110发布了新的文献求助10
18秒前
pjx关注了科研通微信公众号
20秒前
zxx完成签到,获得积分10
20秒前
21秒前
daomaihu发布了新的文献求助100
22秒前
wangmaosen完成签到,获得积分10
23秒前
真实的采白完成签到 ,获得积分10
23秒前
落幕完成签到 ,获得积分10
23秒前
11发布了新的文献求助10
23秒前
贤箪发布了新的文献求助10
25秒前
研友_VZG7GZ的应助被壮观雁易采纳,获得10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184336
求助须知:如何正确求助?哪些是违规求助? 9573358
关于积分的说明 21830993
捐赠科研通 7781367
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558401
邀请新用户注册赠送积分活动 2480846